Re-evaluation showed that for three stroke-genes previously considered suitable for clinical screening, the relevance for stroke had become too inconsistent, and therefore they are now only recommended for research (CACNA1A, MYLK, MFN2), whereas the evidence for 10 other stroke-genes was strengthened and now fulfill our criteria for clinical testing. This evidence concerns the gene MYLK and Stroke.